Study of the pharmacokinetic profile of the medicinal product Gidazepam®, tablets, 50 mg in a bioequivalence study

Aim. The primary aim of this study was to evaluate the pharmacokinetic parameters and confirm the bioequivalence of drugs containing gidazepam, namely Gidazepam® (Valenta Pharm, Russia) and Gidazepam VIC (VIVA Pharm, Republic of Kazakhstan), after a single administration of 1 tablet (50 mg) to healthy volunteers under fasting conditions. The secondary aim was a comparative analysis of safety profiles (adverse events) after a single administration of the studied drugs.

Materials and methods. An open, randomized, crossover, two-period comparative study of pharmacokinetics and bioequivalence with adaptive design was conducted in healthy volunteers. Blood sampling was performed 15 minutes before and 20 min, 40 min, 1 h, 2 h, 3 h, 3.5 h, 4 h, 4.5 h, 5 h, 6 h, 8 h, 12 h, 24 h, 48 h, and 72 h after drug administration. High-performance liquid chromatography-tandem mass spectrometry was used for the evaluation of gidazepam and its metabolite (desalkylgidazepam) concentration with the subsequent calculation of pharmacokinetic parameters.

Results. From both formulations, gidazepam was quickly absorbed and biotransformed into an active metabolite. Studied drugs had similar pharmacokinetic profiles, as 90% confidence intervals for the ratio of geometric means for Cmax and AUC(0-72) were within the bioequivalence acceptance range of 80.00–125.00 %. No adverse events were recorded as a result of clinical, laboratory or instrument evaluations during the study.

Conclusion. Study drugs are considered bioequivalent and show comparable tolerability after a single administration under fasting conditions.

1. Chutko LS, Yakovenko EA, Surushkina SYu, Cherednichenko DV. Neurological aspects of anxiety disorders. Medical alphabet. 2022;(10):7–11. (In Russ.) DOI: 10.33667/2078-5631-2022-10-7-11.

2. Bobrov AE, Usatenko EV. The concept of anxiety disorders: main development trends. Social and clinical psychiatry. 2021;31(4):62–70 (In Russ.).

3. Devlikamova FI, Khaibullina DH, Maksimov YuN, Kadyrova LR. Anxiety disorders in general clinical practice. Meditsinskiy Sovet. 2023;17(6):95–102. (In Russ.) DOI: 10.21518/ms2023-094.

4. Zaripova GR, Garipova JA, Zarudij FS, Yuldashev VL. Contemporary state of problem of pharmaceutical correction in psychosomatic disorders. Bashkortostan medical journal = Meditsinskiy vestnik Bashkortostana. 2010;5(6):127–132. (In Russ.)

5. Korkhov VM, Tkachuk NA, Makan SY, et al. Affinities of gidazepam and its analogs for mitochondrial benzodiazepine receptors. J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):411–420. DOI: 10.1081/rrs-120014610.

6. Sternbach LH. The benzodiazepine story. J Med Chem. 1979 Jan;22(1):1-7. DOI: 10.1021/jm00187a001.

7. Burchinsky SG. Role and place of benzodiazepines in pharmacotherapy of posttraumatic stress disorder. International Neurological Journal. 2018;98(4):68–74. (In Russ.)]. DOI: 10.22141/2224-0713.4.98.2018.139428.

8. Andronati SA, Zin'kovskiĭ VG, Totrova MIu, et al. Biokinetics of a new prodrug gidazepam and its metabolite. Biull Eksp Biol Med. 1992 Jan;113(1):45–47.

9. Kolyvanov GB. Role of pharmacokinetic studies in optimization of dosage forms of drugs with anxiolytic action. Published summary of a dissertation. 2004. Moscow. (In Russ.). URL: https://new-disser.ru/_avtoreferats/01002638230.pdf